Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Cortexyme Secures $125M Private Placement Capital to Advance Clinical Development

Share on Stocktwits


Shares of Cortexyme Inc. traded 20% higher after the company reported that it secured an additional $125M in capital from a private placement. The firm intends to use the proceeds to fund current Alzheimer's clinical trials and ongoing operations.

Clinical stage biopharmaceutical company Cortexyme Inc. (CRTX:NASDAQ), which concentrates its efforts on pioneering a disease-modifying therapeutic approach to treat Alzheimer's and other degenerative diseases, yesterday announced that "it has entered into stock purchase agreements with a group of institutional investors and an entity affiliated with a member of Cortexyme's Board of Directors in connection with a private placement of its common stock."

The company reported that it expects to receive $125 million in gross proceeds prior to incurred transaction expenses. The firm advised that in exchange for investment capital, it will issue 2,500,000 shares of common stock at a purchase price of $50.00 per share. The price was based upon an agreed upon average volume weighted common share price since January 1, 2020 and represents a 9.6% premium to the closing price of the company's common stock on February 5, 2020.

The Company noted that it plans to utilize the net proceeds received primarily to advance clinical development, and for general corporate purposes. The firm indicated that the private placement, which is subject to certain conditions, is expected to close on Monday, February 10, 2020.

Cortexyme is based in South San Francisco, Calif. and describes its business as "a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer's and other degenerative diseases." The company's research is focused on targeting a specific, infectious pathogen found in the brain of Alzheimer's patients that has been tied to neurodegeneration and neuroinflammation in animal models. Cortexyme's lead small molecule is an investigational medicine named COR388 that has advanced through preclinical and Phase 1b testing. The firm is presently conducting the GAIN Phase 2/3 clinical trial of COR388 in patients affected with mild to moderate Alzheimer's disease.

Cortexyme Inc. has a market capitalization of around $1.2 billion with approximately 26.85 million shares outstanding and a short interest of about 5.2%. CRTX shares opened 10% higher today at $50.20 (+$4.56, +9.99%) over yesterday's $45.64 closing price. The stock has traded today between $50.20 to $57.89 per share and is presently trading at $55.70 (+$10.06, +22.04%).


1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe